----

| Nevada                                                        |   | 27-3984713                             |
|---------------------------------------------------------------|--------|----------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |   | (I.R.S. EmployerIdentification Number) |
|                                                          |   |                                   |
| 34 DeForest Ave, Unit 9East Hanover NJ                        |   | 07936                                  |
| (Address of Principal Executive Offices)                      |   | (Zip Code)                             |
|   | Large accelerated filer | ☐                                                          | Accelerated filer         | ☐ |
|--------|-------------------------|------------------------------------------------------------------|---------------------------|---------|
|   | Non-accelerated filer   | ☐  (Do not check if a smaller reporting company) | Smaller reporting company | ☒ |
|   | Emerging growth company | ☐                                                          |                      |    |

----

Table of Contents

|    |                  |                                                                                  | Page   |
|---------|-----------------------|---------------------------------------------------------------------------------------|--------|
| Part I  | Financial Information | 3                                                                                     |
|    | Item 1                | Condensed Consolidated Financial Statements                                           | 3      |
|    |                  | Balance Sheets (Unaudited)                                                            | 3      |
|    |                  | Statements of Operations (Unaudited)                                                  | 4      |
|    |                  | Statements of Cash Flows (Unaudited)                                                  | 5      |
|    |                  | Notes to Financial Statements (Unaudited)                                             | 6      |
|    | Item 2                | Management's Discussion and Analysis of Financial Condition and Results of Operations | 14     |
|    | Item 3                | Quantitative and Qualitative Disclosures About Market Risk                            | 16     |
|    | Item 4                | Controls and Procedures                                                               | 16     |
|    |                  |                                                                                  |   |
| Part II | Other Information     | 17                                                                                    |
|    | Item 1                | Legal Proceedings                                                                     | 17     |
|    | Item 1A               | Risk Factors                                                                          | 17     |
|    | Item 2                | Unregistered Sales of Equity Securities and Use of Proceeds                           | 17     |
|    | Item 3                | Defaults Upon Senior Securities                                                       | 17     |
|    | Item 4                | Mine Safety Disclosures                                                               | 17     |
|    | Item 5                | Other Information                                                                     | 17     |
|    | Item 6                | Exhibits                                                                              | 18     |

----

Table of Contents

| PAZOO, INC.                                                                                                                                 |   |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED BALANCE SHEETS                                                                                                       |   |
| (Unaudited)                                                                                                                                 |   |
|                                                                                                                                        |   |   |   |   |   |   |
|                                                                                                                                        |   | March 31, |   |   | December 31, |   |
|                                                                                                                                        |   | 2017 |   |   | 2016 |   |
|                                                                                                                                        |   |   |   |   |   |   |
| ASSETS                                                                                                                                      |   |   |   |   |   |   |
| Current assets:                                                                                                                             |   |   |   |   |   |   |
| Cash                                                                                                                                        |        | $ | 36,843 |   |   | $ | 88,909 |   |
| Prepaid expenses                                                                                                                            |   |   | 5,536 |   |   |   | 5,536 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total current assets                                                                                                                        |   |   | 42,379 |   |   |   | 94,445 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Fixed assets, net                                                                                                                           |   |   | 566,828 |   |   |   | 613,332 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total assets                                                                                                                                |   | $ | 609,207 |   |   | $ | 707,777 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Current liabilities:                                                                                                                        |   |   |   |   |   |   |   |   |
| Lines of credit                                                                                                                             |   | $ | 19,172 |   |   | $ | 21,039 |   |
| Accounts payable and accrued liabilities                                                                                                    |   |   | 735,411 |   |   |   | 608,332 |   |
| Loans payable                                                                                                                               |   |   | 959,254 |   |   |   | 615,801 |   |
| Interest payable                                                                                                                            |   |   | 1,814,221 |   |   |   | 1,452,102 |   |
| Convertible debt, net of unamortized discounts of $293,166 and $195,827                                                                     |   |   | 1,264,898 |   |   |   | 983,621 |   |
| Contingent consideration liabilities                                                                                                        |   |   | 713,581 |   |   |   | 713,581 |   |
| Derivative liabilities                                                                                                                      |   |   | 3,639,778 |   |   |   | 2,925,627 |   |
| Capital lease liabilities                                                                                                                   |   |   | 373,930 |   |   |   | 373,930 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total current liabilities                                                                                                                   |   |   | 9,520,245 |   |   |   | 7,694,033 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Long-term liabilities:                                                                                                                      |   |   |   |   |   |   |   |   |
| Long-term portion of convertible debt, net of unamortized discounts of $0, and $110,672                                                     |   |   | 1,292,500 |   |   |   | 1,401,828 |   |
| Capital lease liabilities                                                                                                                   |   |   | 85,420 |   |   |   | 136,672 |   |
| Total long-term liabilities                                                                                                                 |   |   | 1,377,920 |   |   |   | 1,538,500 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total liabilities                                                                                                                           |   |   | 10,898,165 |   |   |   | 9,232,533 |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Commitments and contingencies                                                                                                               |   |   |   |   |   |   |   |   |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Stockholders' deficit:                                                                                                                      |   |   |   |   |   |   |   |   |
| Convertible Preferred Stock, 50,000,000 shares authorized, $0.001 par value                                                                 |   |   |   |   |   |   |   |   |
| Series A; 10,000,000 shares authorized, 230,476 and 230,401 shares issued and outstanding, respectively.                                    |   |   | 230 |   |   |   | 230 |   |
| Series B; 5,000,000 shares authorized, 2,150,000 and 1,762,500 shares issued and outstanding, respectively.                            |   |   | 2,150 |   |   |   | 1,762 |   |
| Series C; 10,000,000 shares authorized, 2,621,375 and 2,621,375 shares issued and outstanding, respectively.                           |   |   | 2,621 |   |   |   | 2,621 |   |
| Series D; 12,500,000 shares authorized, 0 and 0 shares issued and outstanding, respectively.                                           |   |   | - |   |   |   | - |   |
| Series E; 12,500,000 shares authorized, 0 and 0 shares issued and outstanding, respectively.                                           |   |   | - |   |   |   | - |   |
| Common stock, $0.001 par value; 2,950,000,000 shares authorized, 10,510,361 and 9,137,630 shares issued and outstanding, respectively. |   |   | 10,510 |   |   |   | 9,138 |   |
| Additional paid-in capital                                                                                                                  |   |   | 12,323,622 |   |   |   | 12,155,641 |   |
| Accumulated deficit                                                                                                                         |   |   | (22,628,091 | ) |   |   | (20,694,148 | ) |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total stockholders' deficit                                                                                                                 |   |   | (10,288,958 | ) |   |   | (8,524,756 | ) |
|                                                                                                                                        |   |   |   |   |   |   |   |   |
| Total liabilities and stockholders' deficit                                                                                                 |   | $ | 609,207 |   |   | $ | 707,777 |   |

----

Table of Contents

| PAZOO, INC.                                                    |   |
|----------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS                |   |
| (Unaudited)                                                    |   |
|                                                           |   |   |   |   |   |   |
|                                                           |   | Three Months Ended |   |
|                                                           |   | March 31, |   |
|                                                           |   | 2017 |   |   | 2016 |   |
|                                                           |   |   |   |   |   |   |
| Revenues:                                                      |   |   |   |   |   |   |
| Management fees - related party                                |   | $ | - |   |   | $ | - |   |
| Advertising Sales                                              |   |   | 51 |   |   |   | 7,326 |   |
| Total revenues                                                 |   |   | 51 |   |   |   | 7,326 |   |
|                                                           |   |   |   |   |   |   |   |   |
| Operating expenses:                                            |   |   |   |   |   |   |   |   |
| Selling, general and administrative expenses                   |   |   | 537,095 |   |   |   | 701,686 |   |
| Professional fees                                              |   |   | 180,004 |   |   |   | 144,443 |   |
| Website setup                                                  |   |   | 1,342 |   |   |   | 4,967 |   |
| Total operating expenses                                       |   |   | 718,441 |   |   |   | 851,096 |   |
|                                                           |   |   |   |   |   |   |   |   |
| Loss from operations                                           |   |   | (718,390 | ) |   |   | (843,770 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Other income/(expenses):                                       |   |   |   |   |   |   |   |   |
| Gain/(loss) on derivative liabilities                          |   |   | (904,409 | ) |   |   | (2,406,761 | ) |
| Gain/(loss) on debt extinguishment                             |   |   | 286,266 |   |   |   | (66,994 | ) |
| Gain on change in fair value of contingent consideration       |   |   | - |   |   |   | 5,000 |   |
| Interest expense                                               |   |   | (597,335 | ) |   |   | (1,029,517 | ) |
| Total other income/(expenses)                                  |   |   | (1,215,478 | ) |   |   | (3,498,272 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Net loss                                                       |   | $ | (1,933,868 | ) |   | $ | (4,342,042 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Series A preferred stock dividends                             |   |   | (19 | ) |   |   | (195 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Net loss attributable to common stockholders                   |   | $ | (1,933,887 | ) |   | $ | (4,342,237 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Net loss per common share – basic and diluted            |   | $ | (0.20 | ) |   | $ | (52.03 | ) |
|                                                           |   |   |   |   |   |   |   |   |
| Weighted average common shares outstanding - basic and diluted |   |   | 9,725,325 |   |   |   | 83,449 |   |

----

Table of Contents

| PAZOO, INC.                                                                 |   |
|-----------------------------------------------------------------------------|--------|
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                             |   |
| (Unaudited)                                                                 |   |
|                                                                        |   |   |   |   |   |   |
|                                                                        |   | Three Months Ended |   |
|                                                                        |   | March 31, |   |
|                                                                        |   | 2017 |   |   | 2016 |   |
|                                                                        |   |   |   |   |   |   |
| Cash flows from operating activities:                                       |   |   |   |   |   |   |
| Net loss                                                                    |   | $ | (1,933,868 | ) |   | $ | (4,342,042 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |   |   |   |   |
| Amortization of debt discounts                                              |   |   | 227,700 |   |   |   | 762,237 |   |
| Depreciation                                                                |   |   | 46,504 |   |   |   | 46,504 |   |
| Amortization                                                                |   |   | - |   |   |   | 25,365 |   |
| Capitalized interest expense                                                |   |   | - |   |   |   | 192,936 |   |
| Change in fair value of contingent consideration                            |   |   | - |   |   |   | (5,000 | ) |
| Stock-based compensation                                                    |   |   | 56,110 |   |   |   | 49,900 |   |
| (Gain)/loss on derivative liabilities                                       |   |   | 904,409 |   |   |   | 2,406,761 |   |
| (Gain)/loss on debt extinguishment                                          |   |   | (286,266 | ) |   |   | 66,994 |   |
| Changes in operating assets and liabilities:                                |   |   |   |   |   |   |   |   |
| Accounts receivable                                                         |   |   | - |   |   |   | (3,842 | ) |
| Prepaid expenses and other current assets                                   |   |   | - |   |   |   | (1 | ) |
| Accounts payable, accrued liabilities and interest payable                  |   |   | 499,546 |   |   |   | 386,924 |   |
| Net cash used in operating activities                                       |   |   | (485,865 | ) |   |   | (413,264 | ) |
|                                                                        |   |   |   |   |   |   |   |   |
| Cash flows from financing activities:                                       |   |   |   |   |   |   |   |   |
| Proceeds from convertible note                                              |   |   | 270,617 |   |   |   | 372,750 |   |
| Repayments on capital leases                                                |   |   | (51,252 | ) |   |   | (31,069 | ) |
| Repayments on convertible notes and loans                                   |   |   | (144,899 | ) |   |   | (9,516 | ) |
| Repayment on loans payable- related party                                   |   |   | (3,300 | ) |   |   | - |   |
| Proceeds from loans payable                                                 |   |   | 364,500 |   |   |   | 39,100 |   |
| Proceeds from sale of Series C preferred stock                              |   |   | - |   |   |   | 50,001 |   |
| Lines of credit                                                             |   |   | (1,867 | ) |   |   | 5,804 |   |
| Net cash provided by financing activities                                   |   |   | 433,799 |   |   |   | 427,070 |   |
|                                                                        |   |   |   |   |   |   |   |   |
| Net (decrease) in cash and cash equivalents                                 |   |   | (52,066 | ) |   |   | 13,806 |   |
|                                                                        |   |   |   |   |   |   |   |   |
| Cash and cash equivalents beginning of period                               |   |   | 88,909 |   |   |   | 16,819 |   |
|                                                                        |   |   |   |   |   |   |   |   |
| Cash and cash equivalents end of period                                     |   | $ | 36,843 |   |   | $ | 30,625 |   |
|                                                                        |   |   |   |   |   |   |   |   |
| Noncash Investing and Financing Activities                                  |   |   |   |   |   |   |   |   |
| Common stock issued for the conversion of Series A preferred stock          |   | $ | - |   |   | $ | 369 |   |
| Debt discount due to derivative liabilities                                 |   |   | 223,604 |   |   |   | 406,336 |   |
| Preferred shares issued for conversion of debt and interest                 |   |   | - |   |   |   | 30,652 |   |
| Common shares issued for conversion of debt and interest                    |   |   | 113,557 |   |   |   | 265,258 |   |

----

Table of Contents

----

Table of Contents

| Potentially Dilutive Securities          |   |           |        |   |           |   |
|------------------------------------------|--------|----------------|-------------|--------|----------------|--------|
|                                     |   | March 31, 2017 |        |   | March 31, 2016 |   |
|                                     |   |           |        |   |           |   |
| Convertible notes                        |   |           | 149,849,934 |   |           |   | 3,392,479 |   |
| Preferred series A shares & warrants |   |           | 23,047,600  |   |           |   | 1,404,613 |   |
| Preferred series B                       |   |           | 430,000,000 |   |           |   | 1,410,000 |   |
| Preferred series C                       |   |           | 262,137,500 |   |           |   | 867,852 |   |
|                                     |   |           | 865,035,034 |   |           |   | 7,074,944 |   |

| Recurring Fair Value Measurements              |   | Level 1 |   | Level 2 |   | Level 3 |   | Total  |   |
|------------------------------------------------|--------|---------|--------|---------|--------|---------|--------|--------|--------|
| LIABILITIES:                                   |   |    |   |    |   |    |   |   |   |
| Derivative liability – March 31, 2017    |   |    | $      | -       |   |    | $      | -      |   |   | $ | 3,639,778 |   |   | $ | 3,639,778 |   |
| Derivative liability – December 31, 2016 |   |    | $      | -       |   |    | $      | -      |   |   | $ | 2,925,627 |   |   | $ | 2,925,627 |   |

----

Table of Contents

----

Table of Contents

| Fixed Assets                              |   |                             |   |   |          |   |     |             |   |
|-------------------------------------------|--------|----------------------------------|--------|--------|---------------|--------|----------|------------------|--------|
|                                      |   | Estimated Useful Life (in years) |   |   | March 31,2017 |   |     | December 31,2016 |   |
|                                      |   |                             |   |   |          |   |     |             |   |
| Cost:                                     |   |                             |   |   |          |   |     |             |   |
| Equipment                                 |   |                             | 3-5    |   |          | $      | 643,195  |             |   | $ | 643,195 |   |
| Furniture and fixture                     |   |                             | 7      |   |          |   | 6,687    |             |   |   | 6,687 |   |
| Leasehold improvements                    |   |                             | 3-5    |   |          |   | 238,620  |             |   |   | 238,620 |   |
| Website                                   |   |                             | 3      |   |          |   | 1,385    |             |   |   | 1,385 |   |
|                                      |   |                             |   |   |          | $      | 889,887  |             |   | $ | 889,887 |   |
|                                      |   |                             |   |   |          |   |     |             |   |   |   |   |
| Accumulated depreciation and amortization |   |                             |   |   |          |   | (323,059 | )                |   |   | (276,555 | ) |
|                                      |   |                             |   |   |          |   |     |             |   |   |   |   |
| Fixed Assets, Net                         |   |                             |   |   |          | $      | 566,828  |             |   | $ | 613,332 |   |

| Balance as of December 31, 2016 |   | $      | 2,925,627 |   |
|---------------------------------|--------|--------|-----------|--------|
|                            |   |   |      |   |
| Grant date fair value           |   |   | 1,217,319 |   |
| Extinguished                    |   |   | (413,862  | )      |
| Change in fair value            |   |   | (89,306   | )      |
|                            |   |   |      |   |
| Balance as of March 31, 2017    |   | $      | 3,639,778 |   |

----

Table of Contents

|                    |   | March 31,2017  |   |   | March 31,2016  |   |
|-------------------------|--------|----------------|--------|--------|----------------|--------|
|                    |   |           |   |   |           |   |
| Dividend yield          |   |           | 0      | %      |           |   | 0 | % |
| Expected volatility     |   |           | 80     | %      |           |   | 80 | % |
| Risk-free interest rate |   | 0.74% to 0.91% |   |   | 0.16% to 0.39% |   |
| Expected life (years)   |   | 0.03 to 0.62   |   |   | 0.04 to 0.86   |   |

|                                    |   | Short Term |      |   | Long Term |   |      | Total  |   |
|-----------------------------------------|--------|------------|-----------|--------|-----------|--------|-----------|--------|--------|
| Balance as of January 1, 2016 - Gross   |   | $          | 1,343,035 |   |      | $      | 992,500   |   |   | $ | 2,335,535 |   |
| Cash additions                          |   |       | 373,460   |   |      |   | 300,000   |   |   |   | 673,460 |   |
| Interest added to notes payable         |   |       | 111,778   |   |      |   | 116,600   |   |   |   | 228,378 |   |
| Cash payments                           |   |       | (118,223  | )      |      |   | -         |   |   |   | (118,223 | ) |
| Conversions                             |   |       | (474,777  | )      |      |   | -         |   |   |   | (474,777 | ) |
| Reassignments                           |   |       | (103,400  | )      |      |   | 103,400   |   |   |   | - |   |
| Original issue discount                 |   |       | 47,575    |   |      |   | -         |   |   |   | 47,575 |   |
| Total                                   |   | $          | 1,179,448 |   |      | $      | 1,512,500 |   |   | $ | 2,691,948 |   |
| Less:  unamortized discount   |   |       | (195,827  | )      |      |   | (110,672  | )      |   |   | (306,499 | ) |
| Balance as of December 31, 2016 - Net   |   | $          | 983,621   |   |      | $      | 1,401,828 |   |   | $ | 2,385,449 |   |
| Add back: unamortized discount          |   |       | 195,827   |   |      |   | 110,672   |   |   |   | 306,499 |   |
| Balance as of December 31, 2016 - Gross |   | $          | 1,179,448 |   |      | $      | 1,512,500 |   |   | $ | 2,691,948 |   |
| Cash additions                          |   |       | 270,617   |   |      |   | -         |   |   |   | 270,617 |   |
| Cash payments                           |   |       | (119,636  | )      |      |   | -         |   |   |   | (119,636 | ) |
| Conversions                             |   |       | (24,927   | )      |      |   | -         |   |   |   | (24,927 | ) |
| Reclassification to short-term          |   |       | 220,000   |   |      |   | (220,000  | )      |   |   | - |   |
| Original issue discount                 |   |       | 32,562    |   |      |   | -         |   |   |   | 32,562 |   |
| Total gross balance                     |   | $          | 1,558,064 |   |      | $      | 1,292,500 |   |   | $ | 2,850,564 |   |
| Less: unamortized discount         |   |       | (293,166  | )      |      |   | -         |   |   |   | (293,166 | ) |
| Balance as of March 31, 2017 - Net      |   | $          | 1,264,898 |   |      | $      | 1,292,500 |   |   | $ | 2,557,398 |   |

|                             |   | Year Ended March 31, |      |
|----------------------------------|--------|----------------------|-----------|
|                             |   | 2018                 |      |   | 2019 |   |   | 2020 |   |   | 2021 |   |   | 2022 |   |   | Thereafter |   |   | Total |   |
| Convertible notes                |   | $                    | 1,558,064 |   |   | $ | - |   |   | $ | - |   |   | $ | 300,000 |   |   | $ | 792,500 |   |   | $ | 200,000 |   |   | $ | 2,850,564 |   |
| Short-term non-convertible notes |   |                 | 959,254   |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 959,254 |   |
|                             |   | $                    | 2,517,318 |   |   | $ | - |   |   | $ | - |   |   | $ | 300,000 |   |   | $ | 792,500 |   |   | $ | 200,000 |   |   | $ | 3,809,818 |   |

----

Table of Contents

|                            |   | Short Term |    |   | Long Term |   |   | Total  |   |
|---------------------------------|--------|------------|---------|--------|-----------|--------|--------|--------|--------|
| Balance as of January 1, 2016   |   | $          | 203,000 |   |      | $      | -      |   |   | $ | 203,000 |   |
| Cash additions                  |   |       | 447,100 |   |      |   | -      |   |   |   | 447,100 |   |
| Interest added to notes payable |   |       | 22,717  |   |      |   | -      |   |   |   | 22,717 |   |
| Cash payments                   |   |       | (57,016 | )      |      |   | -      |   |   |   | (57,016 | ) |
| Balance as of December 31, 2016 |   | $          | 615,801 |   |      | $      | -      |   |   | $ | 615,801 |   |
| Cash additions                  |   |       | 364,500 |   |      |   | -      |   |   |   | 364,500 |   |
| Interest added to notes payable |   |       | 7,516   |   |      |   | -      |   |   |   | 7,516 |   |
| Cash payments                   |   |       | (28,563 | )      |      |   | -      |   |   |   | (28,563 | ) |
| Balance as of March 31, 2017    |   | $          | 959,254 |   |      | $      | -      |   |   | $ | 959,254 |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | ● | Pharmaceutical Testing Facilities.   We entered this arena through our acquisition of a 100% equity stake in MA & Associates, LLC in order to set up two testing locations.   MA & Associates, LLC was launched in September of 2013 to provide quality control services to the medical cannabis industry. MA & Associates, LLC's primary mission is to protect the public health by providing infrastructure and analytical services to legally authorized distributors and producers of cannabis and to regulators tracking their operations. The company will provide the medical cannabis industry guidelines on how the regulation and inspection by public health authorities is to be implemented.  MA & Associates, LLC's primary customer base includes all of the licensed cannabis cultivators, in the State of Nevada, who are required by law to have their products tested before they can be transferred to the dispensaries.  MA & Associates received its operational license from the State of Nevada on January 4, 2017. MA & Associates reported its first revenue through a press release dated May 16, 2017 through PR Newswire. The Company expects to be fully operational and revenue generating in the upcoming months. Furthermore, we have acquired all of the Membership interest in Harris Lee Holdings, LLC. Harris Lee was set up to take the MA model and testing operations to additional states above and beyond Nevada either in direct testing laboratories or through licensing |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  |  | the testing protocol. As such, we are in a unique position to provide the mandated health and safety testing in this burgeoning industry.  Lastly, Harris Lee Holdings, LLC, due to Colorado residency requirements, entered into an advisory agreement with Harris Lee Colorado, LLC, Harris Lee Holdings, LLC has sub-licensed the testing protocols to Harris Lee Colorado, LLC in exchange for a management fee for each test conducted.  The Colorado MED approved the transfer of management of an existing laboratory, operating as Steep Hill Colorado, to Harris Lee Colorado, LLC (a related party) and Harris Lee Holdings, LLC has derived management fees from Harris Lee Colorado, LLC in the year ending December 31, 2016.  All 2016 revenue was derived from these related-party management fees for the year ended December 31, 2016. However, because of the failure to transfer the MED license to Harris Lee Colorado, LLC, the Denver laboratory was closed by the end 2016. Currently, operations have not come back online and the Company is concentrating its focus on MA & Associates, LLC in Nevada. |
|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | ● | Advertising Revenue from our Website, www.pazoo.com.  Through advertising providers and agencies, pazoo.com is paid for every ad impression that appears on a page for which a visitor goes to. As we build our visitor base, ad revenue is anticipated to increase. However, just having the traffic does not effectively increase advertising revenue. To get the full value of each visitor, the time on site must be long enough so that a visitor is interested in going to multiple pages for which there are ads on each page. The only way this will transpire is if the visitor's experience is gratifying. This is why pazoo.com is so focused on quality content that's interesting and informative. A bad visitor experience will result in a low time on site and fewer page views. Internet tracking tools have much improved over the past decade and will continue to improve in the coming years, especially when it comes to advertising and overall website analytics. Pazoo continues to constantly improve is this area at all times. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1. | A comprehensive solution as a content source – information on a full spectrum of disciplines within the health and wellness marketplace; |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 2. | Health and wellness experts that have expertise in these varied disciplines and write about their areas expertise; and |
|--|----|------------------------------------------------------------------------------------------------------------------------|

|  | 3. | Content that is both for the health and wellness of people as well as their pets (over 50% of American homes have pets). |
|--|----|--------------------------------------------------------------------------------------------------------------------------|

|  | 4. | Content in the Health and Wellness sector of cannabis.  To empower users to read and learn about the benefits and the need for the testing of the cannabis plant. |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| ExhibitNumber |   | Description                                                                                                                                                        |
|---------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          |   |                                                                                                                                                               |
| 31.1          |   | Certification of David Cunic, Chairman and Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.                              |
| 31.2          |   | Certification of Ben Hoehn, Acting Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.                                      |
| 32.1          |   | Certification of David Cunic, Chief Executive Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.      |
| 32.2          |   | Certification of Ben Hoehn, Acting Chief Financial Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

----

Table of Contents

| June 16, 2017 | PAZOO, INC.                                                                                          |   |
|---------------|------------------------------------------------------------------------------------------------------|--------|
|          |                                                                                                 |   |
|          | /s/ David M. Cunic                                                                                   |   |
|          | David M. Cunic                                                                                       |   |
|          | Chief Executive Officer                                                                              |   |
|          |                                                                                                 |   |
|          |                                                                                                 |   |
| June 16, 2017 | PAZOO, INC.                                                                                          |   |
|          |                                                                                                 |   |
|          | /s/ Ben Hoehn                                                                                        |   |
|          | Ben Hoehn                                                                                            |   |
|          | Chief Operating Officer, Acting Chief Financial Officer (Principal Financial and Accounting Officer) |   |